Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0609 in advanced solid tumors
NCT07265921Phase 1Recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIM0609 in colorectal carcinoma (CRC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 2 more (5 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Dose-limiting toxicity at 28 days, Safety and Tolerability at 2 years and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
SIM0609
03
Conditions
colorectal carcinoma (CRC)gastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic ductal adenocarcinoma (PDAC)solid tumor
Beyond the preview
Go deeper on NCT07265921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07265921.